Cowen 34th Annual Healthcare Conference in Boston on
Wednesday, March 5, 2014 at 8:40 a.m. ET.
21st Annual Future Leaders in the Biotech Industry Conference in New
York on Friday, March 28, 2014 at 9:00 a.m. ET. Interested parties may
access a live webcast of this presentation by visiting the Eleven
Biotherapeutics website at www.elevenbio.com.
The webcast will be archived on the Eleven Biotherapeutics website
following the event for one week.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage
biopharmaceutical company discovering and developing protein
therapeutics to treat diseases of the eye, today announced that Abbie
Celniker, Ph.D., Elevenís President and CEO, is scheduled to present at
the following healthcare conferences during March 2014.
About Eleven Biotherapeutics
Eleven Biotherapeutics (NASDAQ:EBIO) is a clinical-stage
biopharmaceutical company with a proprietary protein engineering
platform, called AMP-Rx, that it applies to the discovery and
development of protein therapeutics to treat diseases of the eye. The
companyís therapeutic approach is based on the role of cytokines in
diseases of the eye, the companyís understanding of the structural
biology of cytokines and the companyís ability to rationally design and
engineer proteins to modulate the effects of cytokines. Cytokines are
cell signaling molecules found in the body that can have important
inflammatory effects. www.elevenbio.com
Cameron Wheeler, PhD, 617-858-0927
Gina Nugent, 617-460-3579
Source: Eleven Biotherapeutics